Halozyme to Report Second Quarter 2026 Financial and Operating Results

Rhea-AI Summary

Halozyme (Nasdaq: HALO) plans to release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the U.S. market close. The company will host a results conference call that day at 1:30 p.m. PT / 4:30 p.m. ET, with live access via pre-registration link and webcast replay available in the Investors section of its website.

News Market Reaction – HALO

+3.88%

2 alerts

+3.88% Session close to close

$9.23B Market Cap

0.5x Rel. Volume

In the Jul 23 session, HALO gained 3.88%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Historical earnings-date reactions were +0.47% and -0.89%, framing this notice as a mixed precedent....

Analysis

Historical earnings-date reactions were +0.47% and -0.89%, framing this notice as a mixed precedent. The August 6 release is the next checkpoint, while recent Net Selling insider activity adds a sourced risk factor.

Key Figures

Reporting period: Second quarter 2026 Results release date: August 6, 2026 Conference call time: 1:30pm PT / 4:30pm ET

3 metrics

Reporting period Second quarter 2026 Financial and operating results

Results release date August 6, 2026 Following the close of trading

Conference call time 1:30pm PT / 4:30pm ET August 6, 2026

Previous Earnings date Reports

2 past events · Latest: Apr 30 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Earnings date	Neutral	+0.5%	Scheduled Q1 2026 results release and conference call after market close
Feb 10	Earnings date	Neutral	-0.9%	Scheduled Q4 and full-year 2025 results release after market close

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date announcements produced mixed reactions, with an average move of -0.21%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading.

Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/838122249?pwd=X5tkHKiy

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com 

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2026-financial-and-operating-results-302832891.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme (NASDAQ: HALO) report its Q2 2026 earnings results?

Halozyme plans to release its Q2 2026 financial and operating results on Thursday, August 6, 2026, after the close of trading. According to Halozyme, the announcement will be followed by a same-day conference call to discuss the reported results in more detail.

What time is the Halozyme (HALO) Q2 2026 earnings conference call on August 6, 2026?

Halozyme will host its Q2 2026 earnings conference call on August 6, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. According to Halozyme, the call will follow the earnings release issued after market close that same day for investors and analysts.

How can investors access the Halozyme (HALO) Q2 2026 earnings call webcast?

Investors can access Halozyme’s Q2 2026 earnings call via a live webcast in the Investors section of www.halozyme.com. According to Halozyme, a replay of the webcast will also be available on the company’s website after the live event concludes.

Is pre-registration required for the Halozyme (HALO) Q2 2026 earnings conference call?

Yes, the Halozyme Q2 2026 earnings conference call may be accessed live with pre-registration via the provided online link. According to Halozyme, registered participants can join the live discussion of the company’s quarterly financial and operating results on August 6, 2026.

Will there be a replay of the Halozyme (HALO) Q2 2026 earnings call for shareholders?

Yes, Halozyme will offer a webcast replay of its Q2 2026 earnings call. According to Halozyme, both the live webcast and subsequent replay will be available through the Investors section of the company’s corporate website at www.halozyme.com for later listening.